Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline

[1]  Michael R. Duggan,et al.  Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology. , 2024, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[2]  S. Resnick,et al.  Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk , 2023, Annals of neurology.

[3]  J. Kramer,et al.  Plasma phosphorylated tau‐217 exhibits sex‐specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults , 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  K. Blennow,et al.  Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease , 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  L. Ferrucci,et al.  Longitudinal changes in Alzheimer's‐related plasma biomarkers and brain amyloid , 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[6]  K. Blennow,et al.  Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease , 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  S. Lehmann,et al.  Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort , 2023, Alzheimer's Research & Therapy.

[8]  M. Mintun,et al.  Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease , 2022, JAMA Neurology.

[9]  K. Blennow,et al.  Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration , 2022, Alzheimer's Research & Therapy.

[10]  C. Rowe,et al.  Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[11]  Hui Huang,et al.  Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum , 2022, Frontiers in Aging Neuroscience.

[12]  K. Blennow,et al.  Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility , 2022, Nature Reviews Neurology.

[13]  Keith A. Johnson,et al.  Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. , 2022, Journal of Alzheimer's disease : JAD.

[14]  Derek H. Oakley,et al.  Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment , 2022, Frontiers in Neurology.

[15]  R. D. De Sousa.  Reactive gliosis in Alzheimer’s disease: a crucial role for cognitive impairment and memory loss , 2022, Metabolic Brain Disease.

[16]  S. O'Bryant,et al.  Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[17]  S. Resnick,et al.  Vascular risk is not associated with PET measures of Alzheimer's disease neuropathology among cognitively normal older adults. , 2021, Neuroimage. Reports.

[18]  N. Powe,et al.  A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. , 2021, Journal of the American Society of Nephrology : JASN.

[19]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[20]  K. Blennow,et al.  Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease , 2021, JAMA neurology.

[21]  N. Powe,et al.  A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  T. Schneider-Axmann,et al.  Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[23]  J. Kramer,et al.  Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment , 2021, Journal of the International Neuropsychological Society.

[24]  K. Blennow,et al.  Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[25]  O. Hansson.  Biomarkers for neurodegenerative diseases , 2021, Nature Medicine.

[26]  L. Tan,et al.  Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET , 2021, Alzheimer's Research & Therapy.

[27]  H. Potter,et al.  Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease , 2021, Neurobiology of Aging.

[28]  K. Blennow,et al.  Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease , 2021, JAMA neurology.

[29]  K. Blennow,et al.  Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. , 2020, Brain : a journal of neurology.

[30]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[31]  J. Kramer,et al.  Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage. , 2020, Journal of Alzheimer's disease : JAD.

[32]  J. Weuve,et al.  Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study , 2020, Annals of neurology.

[33]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[34]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[35]  Yuan Cheng,et al.  Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives , 2020, Translational Neurodegeneration.

[36]  Philip S. Insel,et al.  Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease , 2020, Science Advances.

[37]  Albert Hofman,et al.  Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study , 2020, Brain : a journal of neurology.

[38]  G. Winterer,et al.  Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls , 2020, Journal of Alzheimer's disease : JAD.

[39]  C. Enzinger,et al.  Serum neurofilament light levels in normal aging and their association with morphologic brain changes , 2020, Nature Communications.

[40]  S. Resnick,et al.  Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[42]  Christos Davatzikos,et al.  DeepMRSeg: A convolutional deep neural network for anatomy and abnormality segmentation on MR images , 2019, ArXiv.

[43]  K. Blennow,et al.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.

[44]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[45]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[46]  K. Blennow,et al.  Plasma β-amyloid in Alzheimer’s disease and vascular disease , 2016, Scientific Reports.

[47]  G. Bloom.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.

[48]  L. Ferrucci.  The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[49]  S. Resnick,et al.  Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain , 2003, The Journal of Neuroscience.

[50]  Dinggang Shen,et al.  Very High-Resolution Morphometry Using Mass-Preserving Deformations and HAMMER Elastic Registration , 2003, NeuroImage.

[51]  A. Pfeufer,et al.  TaqMan Systems for Genotyping of Disease-Related Polymorphisms Present in the Gene Encoding Apolipoprotein E , 2002, Clinical chemistry and laboratory medicine.

[52]  Christos Davatzikos,et al.  Voxel-Based Morphometry Using the RAVENS Maps: Methods and Validation Using Simulated Longitudinal Atrophy , 2001, NeuroImage.

[53]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[54]  R. Petersen,et al.  Aging, Memory, and Mild Cognitive Impairment , 1997, International Psychogeriatrics.

[55]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[56]  I. Rossman,et al.  Normal Human Aging: The Baltimore Longitudinal Study of Aging , 1986 .

[57]  J. R. Wilson,et al.  Cognitive Abilities: Use of Family Data as a Control to Assess Sex and Age Differences in Two Ethnic Groups , 1975, International journal of aging & human development.

[58]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .